Target family: Calcitonin receptors (type: gpcr)
Target: AMY<sub>1</sub> receptor

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
Published in: Endocrinology

Ligand: β-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.2 pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: β-CGRP (Peptide)
Interaction type: Agonist
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: calcitonin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1986)
Median affinity:  pEC50
Reference (Journal): Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition.
Published in: Biochem J

Ligand: calcitonin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1986)
Median affinity:  pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: calcitonin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1986)
Median affinity:  pEC50
Reference (Journal): Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor.
Published in: J Pharmacol Toxicol Methods

Ligand: calcitonin (salmon) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: no
Median affinity:  -

Ligand: calcitonin (salmon) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: no
Median affinity: 9 pKi
Reference (Journal): Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product.
Published in: Mol Pharmacol

Ligand: CT-(8-32) (salmon) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.78000020980835 pKi
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: [Cys(Et)2,7]α-CGRP (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins.
Published in: Mol Pharmacol

Ligand: [Cys(Et)2,7]α-CGRP (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: olcegepant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.5 pKB
Reference (Journal): Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors--the role of receptor activity modifying protein 1.
Published in: Mol Pharmacol

Ligand: pramlintide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2005)
Primary target: no
Median affinity:  pEC50
Reference (Journal): Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
Published in: Endocrinology

Ligand: rimegepant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2020), EMA (2022)
Primary target: no
Median affinity: 8.100000381469727 pKB
Reference (Journal): Antagonism of CGRP Signaling by Rimegepant at Two Receptors.
Published in: Front Pharmacol

Ligand: [125I]BH-AMY (rat, mouse) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd

Ligand: [125I]αCGRP (human) (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd

Ligand: Tyr0α-CGRP (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Median affinity:  pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: Tyr0α-CGRP (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Median affinity:  pEC50
Reference (Journal): Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins.
Published in: Mol Pharmacol